Source: International Congress 2017 – Silicosis has not gone away
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
C. Xue (BEIJING, China). Serum KL-6, SP-D and MMP-2 as diagnostic biomarkers in asbestosis and silicosis. 488

Member's Comments

No comment yet.

Related content which might interest you: Comparative study of CC16, KL-6 and SP-D as serum markers in sarcoid patients Source: Eur Respir J 2002; 20: Suppl. 38, 173s Year: 2002 Serum KL-6 as a marker of disease progression in SSc-ILD Source: International Congress 2018 – CTD-ILD and hypersensitivity pneumonitis: from the bench to the bedside Year: 2018 Human napsin a is a useful serum marker of interstitial lung disease, compared to KL-6, and surfactant protein-D Source: Annual Congress 2009 - Bronchoalveolar lavage and phenotyping in diffuse parenchymal lung disease Year: 2009 YKL-40 and KL-6 in serum and sputum samples of patients diagnosed with hypersensitivity pneumonitis. Source: International Congress 2019 – Environment, work and respiratory health in occupational and environmental lung diseases Year: 2019 Serum concentrations of KL-6 in patients with IPF and lung cancer and serial measurements of KL-6 in IPF patients treated with antifibrotic therapy Source: Virtual Congress 2021 – Biomarkers and e-health in idiopathic interstitial pneumonia Year: 2021 KL-6 is a useful serum biomarker for early detection of interstitial lung disease Source: Annual Congress 2012 - Diffuse parenchymal lung disease pathogenesis, biomarkers, therapy and new entities Year: 2012 Serum and BALF levels of YKL-40 in patients with alveolar proteinosis Source: Annual Congress 2010 - Biomarkers in diffuse parenchymal lung disease Year: 2010 High serum levels of YKL-40 in IPF Source: Annual Congress 2008 - Novel mechanisms and targets of molecular pulmonary pathology Year: 2008 Prognostic value of circulating KL-6 in idiopathic pulmonary fibrosis Source: Annual Congress 2004 - Fibrosing lung diseases Year: 2004 PP102 – A serum biomarker reflecting human neutrophil elastase degraded calprotectin is elevated in COPD and IPF Source: ERS Lung Science Conference 2021 Year: 2021 Different concentrations of CCL18 in serum and BALF of ILDs: A marker of pulmonary inflammation? Source: Annual Congress 2010 - Usefulness of bronchoalveolar lavage in diffuse parenchymal lung disease Year: 2010 Serum markers of IPF Source: Research Seminar 2004 - Genotyping and Phenotyping of Diffuse Parenchymal Lung Diseases Year: 2004 Serum CC16 is a potential predictor for IPF diagnosis and prognosis Source: Virtual Congress 2020 – Prognosis and biomarkers of idiopathic pulmonary fibrosis Year: 2020 Usefulness of serum procalcitonin levels in pulmonary tuberculosis Source: Eur Respir J 2011; 37: 371 Year: 2011 Elevated serum S100A4 levels in patients with silicosis Source: International Congress 2019 – New mechanistic insights into pulmonary fibrosis Year: 2019 Serum levels of chitotriosidase in pulmunary sarcoidosis Source: Annual Congress 2008 - COPD and other environment-related lung diseases Year: 2008 Serum neopterin and IL-6 as biomarkers in patients with COPD. Source: International Congress 2017 – Novel molecular and genetic targets in COPD Year: 2017 The serum YKL-40 is a useful biomarker for asthma Source: International Congress 2017 – Techniques to treat asthma Year: 2017 The significance of serum CA-125 and various tumour markers in pulmonary and pleural tuberculosis Source: Eur Respir J 2003; 22: Suppl. 45, 156s Year: 2003 Elevated serum IL-8: a biomarker indicating exacerbation-prone COPD Source: International Congress 2017 – COPD biomarkers Year: 2017